Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells (Q93336053)

From Wikidata
Jump to navigation Jump to search
scientific article published on 21 November 2018
edit
Language Label Description Also known as
English
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells
scientific article published on 21 November 2018

    Statements

    title
    Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells (English)
    1 reference
    stated in
    Europe PubMed Central
    PubMed publication ID
    30463991
    reference URL
    https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30463991%20AND%20SRC:MED&resulttype=core&format=json
    retrieved
    5 May 2020
    author

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q93336053&oldid=2172120062"